Researchers create a promising new treatment for the deadliest form of brain cancer

September 2, 2015 by Reggie Kumar
Glioblastoma (histology slide). Credit: Wikipedia/CC BY-SA 3.0

UCLA scientists have developed a potentially promising new combination therapy for glioblastoma, the most common and deadliest form of brain cancer.

Glioblastoma, also known as grade IV glioma, is an aggressive in humans. Approximately 23,000 people in the U.S. are diagnosed with glioblastoma every year. Patients usually receive surgery, chemotherapy and radiation, but these treatments are not very effective as an estimated 50 percent of GBM patients die within one year, and 90 percent die within three years.

A study led by Dr. Robert Prins and Dr. Linda Liau, both members of the UCLA Jonsson Comprehensive Cancer Center, looked at the impact of a combined treatment using a chemotherapy drug called decitabine and genetically modified immune cells. It is a continuation of previous research, published in 2011, that focused on the effect of decitabine on glioblastoma human cell cultures.

In the new research, Prins and Liau used a technique called engineered adoptive T cell transfer, which involves extracting and growing immune cells outside of the body, then reprogramming them with the gene for a T cell receptor targeting New York esophageal squamous carcinoma, or NY-ESO-1. They are then injected back into mice with glioblastoma tumors to produce an immune response that targets the .

Glioblastoma cells do not naturally produce NY-ESO-1, so the researchers administered decitabine prior to injecting the reprogrammed T cells in order to cause the to express the NY-ESO-1 target.

"The lymphocytes will seek out and find the in the brain," said Prins, UCLA associate professor in the departments of neurosurgery and molecular and medical pharmacology. "They can cross different fiber tracts in the brain to reach tumor cells that have migrated away from the main tumor mass. These factors are important in the treatment of invasive tumors, such as glioblastoma. While surgery to remove the main tumor mass can be done, it is not possible to then locate the tumor cells that get away and this ultimately leads to a nearly universal tumor regrowth."

This new method was about 50 percent effective at curing glioblastoma in the study.

"Brain cancer cells are very good at evading the host immune system, because they do not express specific targets that can be recognized by ," said Liau, UCLA professor and vice chair of neurosurgery.

"By treating cells with decitabine, we found that we can unmask targets on the tumor cell that can be recognized by killer T cells. Once these targets are uncovered, we can then administer T cells that are genetically programmed to attack tumor cells with the new targets."

The next stage of Prins' and Liau's research will verify these findings in other brain tumor models.

This research will be published today in the journal Neuro-Oncology.

Explore further: Researchers identify protein pathway involved in brain tumor stem cell growth

Related Stories

Researchers identify protein pathway involved in brain tumor stem cell growth

February 26, 2015
Glioblastomas are a highly aggressive type of brain tumor, with few effective treatment options. Moffitt Cancer Center researchers are one step closer to understanding glioblastoma development following the identification ...

Killer cocktail fights brain cancer

November 25, 2013
A novel immune-boosting drug combination eradicates brain cancer in mice, according to a study in The Journal of Experimental Medicine.

Epigenetic driver of glioblastoma provides new therapeutic target

July 6, 2015
Cancer's ability to grow unchecked is often attributed to cancer stem cells, a small fraction of cancer cells that have the capacity to grow and multiply indefinitely. How cancer stem cells retain this property while the ...

Research finds no correlation between regulatory T cells and survival in glioblastoma

April 16, 2015
Using a novel methodology of epigenetic quantitative analysis, Dartmouth-Hitchcock's Norris Cotton Cancer Center's interdisciplinary team of investigators led by Camilo Fadul, MD, found no correlation between regulatory T ...

In lab tests, new therapy slows spread of deadly brain tumor cells

July 27, 2015
The rapid spread of a common and deadly brain tumor has been slowed down significantly in a mouse model by cutting off the way some cancer cells communicate, according to a team of researchers that includes UF Health faculty.

Team discovers mechanism responsible for tumor invasion in brain cancer

April 9, 2015
A neuro-oncology research team at Dartmouth's Norris Cotton Cancer Center, led by the Director Mark A. Israel, MD with first author Gilbert J. Rahme, PhD, recently identified the transcription factor Id4 as a suppressor of ...

Recommended for you

Tracking how multiple myeloma evolves by sequencing DNA in the blood

December 10, 2017
Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back. Following genetic changes in how the disease evolves over time will help to understand the disease and, ...

Landmark CAR-T cancer study published

December 10, 2017
Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells.

Study finds emojis promising tool for tracking cancer patients' quality of life

December 10, 2017
In findings presented to the American Society of Hematology, Mayo Clinic researchers found that using emojis instead of traditional emotional scales were helpful in assessing patients' physical, emotional and overall quality ...

Study explores use of checkpoint inhibitors after relapse from donor stem cell transplant

December 10, 2017
Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who relapse after a transplant with donor stem cells. Preliminary results from the first clinical trial ...

Blood test may help predict which breast cancers will recur

December 8, 2017
A blood test five years after breast cancer treatment helped identify some women who were more likely to relapse, long before a lump or other signs appeared, a preliminary study found.

Alcohol-abuse drug Antabuse kills cancer cells

December 8, 2017
A new study in Nature by an international team including researchers from Karolinska Institutet, reports that the alcohol-abuse drug Antabuse is effective against cancer. The study also identifies a potential mechanism of ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

the masked scientist
not rated yet Sep 03, 2015
One should watch " Burzynski the movie" which discusses this cancer. While his work has been vilified a recent study in PLOS One concludes "....We conclude that in this study antineoplastons have demonstrated a promising level of efficacy against postoperative recurrence with a median CSS time of 67 months in the AN arm versus 39 months in the control arm, achieved via inhibition of early growth in metastatic tumors from colorectal cancer. The administration of antineoplaston AS2–1 may be clinically effective as a postoperative adjuvant therapy in liver metastasis from colorectal cance" citation Ogata Y, Matono K, Tsuda H, Ushijima M, Uchida S, Akagi Y, et al. (2015) Randomized Phase II Study of 5-Fluorouracil Hepatic Arterial Infusion with or without Antineoplastons as an Adjuvant Therapy after Hepatectomy for Liver Metastases from Colorectal Cancer. PLoS ONE 10(3): e0120064. doi:10.1371/journal.pone.0120064

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.